Capricor Therapeutics, Inc. (CAPR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SCYNEXIS, Inc.

FibroGen, Inc.

Capricor Therapeutics, Inc.

CytomX Therapeutics, Inc.

Aquestive Therapeutics, Inc.

Chimerix, Inc.

aTyr Pharma, Inc.

Achieve Life Sciences, Inc.

Atossa Therapeutics, Inc.

Anebulo Pharmaceuticals, Inc.

Annovis Bio, Inc.

Why is Capricor Therapeutics, Inc. ?

The company has declared Negative results for the last 4 consecutive quarters

NET SALES(9M) At USD 11.13 MM has Grown at -46.91%
OPERATING CASH FLOW(Y) Lowest at USD -52.99 MM
RAW MATERIAL COST(Y) Grown by 101.11% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -75.56%, its profits have fallen by -126.5%

Below par performance in long term as well as near term

Along with generating -75.56% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Capricor Therapeutics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Capricor Therapeutics, Inc.

53.85%

-0.13

115.32%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

69.01%

EBIT Growth (5y)

-245.08%

EBIT to Interest (avg)

-30.73

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.10

Sales to Capital Employed (avg)

1.26

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

54.12%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.10

EV to EBIT

-8.90

EV to EBITDA

-9.14

EV to Capital Employed

-39.48

EV to Sales

29.36

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-43.14%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

CASH AND EQV(HY)

Highest at USD 267.58 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 62.36 times

-26What is not working for the Company

NET SALES(9M)

At USD 11.13 MM has Grown at -46.91%

OPERATING CASH FLOW(Y)

Lowest at USD -52.99 MM

RAW MATERIAL COST(Y)

Grown by 101.11% (YoY

OPERATING PROFIT(Q)

Lowest at USD -27.23 MM

PRE-TAX PROFIT(Q)

Lowest at USD -25.91 MM

NET PROFIT(Q)

Lowest at USD -25.91 MM

EPS(Q)

Lowest at USD -0.57

Here's what is working for Capricor Therapeutics, Inc.

Cash and Eqv

Highest at USD 267.58 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debtors Turnover Ratio

Highest at 62.36 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Capricor Therapeutics, Inc.

Net Sales

At USD 11.13 MM has Grown at -46.91%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -25.91 MM has Fallen at -88.22%

over average net sales of the previous four periods of USD -13.77 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -25.91 MM has Fallen at -88.22%

over average net sales of the previous four periods of USD -13.77 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -52.99 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Operating Profit

Lowest at USD -27.23 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Pre-Tax Profit

Lowest at USD -25.91 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -25.91 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

EPS

Lowest at USD -0.57

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost

Grown by 101.11% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales